PTH 1-34 Replacement Therapy Has Minimal Effect on Quality of Life in Patients With Hypoparathyroidism
| Autor: | Lori C. Guthrie, Kelly L Roszko, Tiffany Y. Hu, Beth A Brillante, Michaele Smith, Rachel I Gafni, Michael T. Collins |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
education.field_of_study
medicine.medical_specialty business.industry Hormone Replacement Therapy Hypoparathyroidism Endocrinology Diabetes and Metabolism Population Parathyroid hormone medicine.disease Health Surveys Article Discontinuation Bodily pain Minimal effect Quality of life Internal medicine Quality of Life Medicine Humans Orthopedics and Sports Medicine In patient education business hormones hormone substitutes and hormone antagonists |
| Zdroj: | J Bone Miner Res |
| ISSN: | 1523-4681 |
| Popis: | In addition to hypocalcemia, patients with hypoparathyroidism report poor quality of life (QOL), complaining of fatigue and "brain fog." Parathyroid hormone (PTH) therapy can effectively manage hypocalcemia; however, the effects of PTH treatment on QOL are unclear. Thirty-one patients with hypoparathyroidism were treated in an open-label study with full replacement subcutaneous PTH 1-34 twice daily for up to 5.3 years, with individualized fine-dosing titration. Prior to initiation of PTH 1-34, conventional therapy was optimized. The 36-Item Short Form (SF-36) Health Survey, Fatigue Symptom Inventory (FSI), and 6-minute walk test (6MWT) were assessed at PTH start (baseline), every 6 months on PTH, and after PTH discontinuation. The SF-36 assesses physical function (PF), physical role limitations (RP), bodily pain (BP), general health (GH), vitality (VT), emotional role limitations (RE), social function (SF), and mental health (MH). Compared to population norms, patients at baseline had lower scores in RP, GH, VT, and MH (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text